You are here

SARC005

Completed
Adjuvant treatment of high risk uterine leiomyosarcoma with gemcitabine/docetaxel, followed by: a phase II multi-center trial
Type of Sarcoma: 
Uterine Leiomyosarcoma
Drug: 
Gemcitabine and Docetaxel
Accrual Status: 
Closed
Overall Study Principal Investigator: 

Martee L. Hensley, MD
Memorial Sloan Kettering Cancer Institute

For more information about this trial and open sites: